Caffeine and Cognitive Decline in Elderly Women at High Vascular Risk
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Persons with vascular disorders are at higher risk of cognitive decline. OBJECTIVE: To determine whether caffeine may be associated with cognitive decline reduction in elderly at high vascular risk. METHODS: We included 2,475 women aged 65+ years in the Women's Antioxidant Cardiovascular Study, a randomized trial of antioxidants and B vitamins for cardiovascular disease secondary prevention. We ascertained regular caffeine intake at baseline (1995-1996) using a validated 116 item-food frequency questionnaire. From 1998-2000 to 2005-2006, we administered four telephone cognitive assessments at two-year intervals evaluating global cognition, verbal memory, and category fluency. The primary outcome was the change in global cognitive score, which was the average of the z-scores of all tests. We used generalized linear models for repeated measures that were adjusted for various sociodemographic, health, and lifestyle factors to evaluate the difference in cognitive decline rates across quintiles of caffeine intake. RESULTS: We observed significantly slower rates of cognitive decline with increasing caffeine intake (p-trend = 0.02). The rate difference between the highest and lowest quintiles of usual caffeine intake (>371 versus <30 mg/day) was equivalent to that observed between those who were 7 years apart in age (p = 0.006). Consumption of caffeinated coffee was significantly related to slower cognitive decline (p-trend = 0.05), but not other caffeinated products (e.g., decaf, tea, cola, chocolate). We conducted interaction analyses and observed stronger associations in women assigned to vitamin B supplementation (p-interaction = 0.02). CONCLUSIONS: Caffeine intake was related to moderately better cognitive maintenance over 5 years in older women with vascular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Total energy intake: implications for epidemiologic analyses.
WILLETT, W., & STAMPFER, M. J. (1986) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114366 · Cited by 2,751
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 2×
“blockade of adenosine A2A receptors [1], which may attenuate damage caused by betaamyloid, the toxic peptide that accumulates in the brain of patients with Alzheimer disease (AD) [33].”
Food sources and intakes of caffeine in the diets of persons in the United States
Frary, C. D., Johnson, R. K., & Wang, M. Q. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.10.027 · Cited by 681
Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review
van Dam, R. M., & Hu, F. B. (2005) · JAMA · doi:10.1001/jama.294.1.97 · Cited by 662 · cited 2×
“Another neuroprotective mechanism for caffeine would involve improving insulin sensitivity [37] and reducing the risk of diabetes [11], which is a strong risk factor for cognitive decline; this pathway would be particularly more relevant in populations with CVD or cardiovascular risk factors such as ours.”
The neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Self-citationArendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Coffee, Caffeine, and Risk of Depression Among Women
Lucas, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.393 · Cited by 270 · cited 1×
“More generally, protective effects of caffeine in cognitive aging could also be mediated through benefits on psychological factors, as caffeine may improve depressive symptoms [38], which, in turn, may protect against decline in cognitive functioning [39].”
van Gelder, B. M., Buijsse, B., Tijhuis, M., Kalmijn, S., Giampaoli, S., Nissinen, A., & Kromhout, D. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602495 · Cited by 228
Wu, J.-N., Ho, S. C., Zhou, C., Ling, W.-H., Chen, W.-Q., Wang, C.-L., & Chen, Y.-M. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.051 · Cited by 185 · cited 2×
“Results from previous studies suggest that women may be more sensitive than men to the positive effects of caffeine against both cardiovascular risk [12] and cognitive aging [31].”
Peters, N., Opherk, C., Danek, A., Ballard, C., Herzog, J., & Dichgans, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2078 · Cited by 178
Verhoef, P., Pasman, W. J., van Vliet, T., Urgert, R., & Katan, M. B. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.6.1244 · Cited by 158 · cited 1×
“An adverse effect of high coffee intake is the elevation of homocysteine [40], which is neurotoxic [41], and it has previously been reported that the cytogenetic damage induced by folate deficiency in mice was enhanced by large amounts of caffeine [42].”
Kang, J. H., Cook, N. R., Manson, J. E., Buring, J. E., Albert, C. M., & Grodstein, F. (2009) · Circulation · doi:10.1161/circulationaha.108.816900 · Cited by 136
Self-citationCoffee Intake in Midlife and Risk of Dementia and its Neuropathologic Correlates
Gelber, R. P., Petrovitch, H., Masaki, K. H., Ross, G. W., & White, L. R. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101428 · Cited by 133
Duarte, J. M. N., Agostinho, P. M., Carvalho, R. A., & Cunha, R. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0021899 · Cited by 130
A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease
Kang, J. H., Cook, N., Manson, J., Buring, J. E., Albert, C. M., & Grodstein, F. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26404 · Cited by 114 · cited 1×
“Until the scheduled end in 2005, participants completed annual questionnaires on compliance, side of the supplements were found to reduce CVD recurrence [15, 16] or influence cognitive decline [17, 18].”
Self-citationCaffeine Intake is Associated with a Lower Risk of Cognitive Decline: A Cohort Study from Portugal
Santos, C., Lunet, N., Azevedo, A., de Mendonça, A., Ritchie, K., & Barros, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091303 · Cited by 100
Self-citationArab, L., Biggs, M. L., O'Meara, E. S., Longstreth, W. T., Crane, P. K., & Fitzpatrick, A. L. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110431 · Cited by 98
Cited by
The Safety of Ingested Caffeine: A Comprehensive Review
Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00080 · Cited by 557
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Coffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Solfrizzi, V., and for the Italian Longitudinal Study on Aging Working Group 2, Panza, F., Imbimbo, B. P., D’Introno, A., Galluzzo, L., Gandin, C., Misciagna, G., Guerra, V., Osella, A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150333 · Cited by 65
Liu, X., Du, X., Han, G., & Gao, W. (2017) · Oncotarget · doi:10.18632/oncotarget.17429 · Cited by 60
Metadata
- Authors
- Vercambre, M.-N., Berr, C., Ritchie, K., & Kang, J. H.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-04-17
- Volume
- 35
- Issue
- 2
- Pages
- 413-421
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1508789589
- Cited by
- 66
- References
- 17
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.